Jump to Navigation

Facebook Connect

User login

nla



Overview


We invite you to join the National Lipid Association in San Diego, California for the 2016 Spring Clinical Lipid Update, March 18-20, at the Omni Hotel.

Don't Miss our Featured Sessions:

  • PCSK9 Inhibition: A New Paradigm in LDL-C Reduction
  • New Advances in the Treatment of Familial Hypercholesterolemia
  • Debates in Lifestyle Therapy
  • Keeping Up to Date in Clinical Lipidology
  • Application of Innovative Diagnostic Techniques to the Practice of Clinical Lipidology
  • Update on Lipid Management in Special Populations

 

 

Endorsed by the California Chapter of the
American College of Cardiology.
California Chapter of the ACC

 

 

 

 

 

 

 

 

 

 

Agenda


Friday, March 18, 2016

Session I: PCSK9 inhibition: A New Paradigm in LDL-C Reduction
3:40- 3:50 PM
Chapter Presidents Welcome & Introduction
3:50- 4:00 PM
ARS Questions
4:00- 4:30 PM
PCSK9 Inhibitors: Do the FDA-Approved Indications Mandate Lipid Goals?- NON CME/CE
Jane F. Barlow, MD, MPH, MBA
4:30- 5:00 PM
PCSK9 Inhibitors: Impact on the Management of LDL Apheresis Candidates and LDL Apheresis Patients
Anne C. Goldberg, MD, FNLA
5:00- 5:30 PM
PCSK9 Inhibitors: Should they be used in Statin Intolerant Patients?
Terry A. Jacobson, MD, FNLA
5:30- 6:00 PM
ARS Questions and Q&A Panel
6:00- 7:00 PM
Welcome Reception in Exhibit Hall

Saturday, March 19, 2016

6:00- 7:45 AM
Current Controversies in Dyslipidemia Management: A Point-Counterpoint Discussion- Breakfast Symposium
7:00- 7:50 AM
Breakfast in Exhibit Hall
Session II: Keeping Up to Date in Clinical Lipidology
7:50- 8:00 AM
Housekeeping Notes & ARS Questions for Session II
8:00- 8:30 AM
Using Big Data: The Very Large Database of Lipids
Seth S. Martin, MD, MHS, FACC
8:30- 9:00 AM
Key Clinical Lipidology Articles in 2015-2016
Kevin C. Maki, PhD, CLS, FNLA
9:00- 9:30 AM
Key Clinical Lipidology Research in Progress in 2016
Harold E. Bays, MD, FNLA
9:30- 10:00 AM
ARS Questions and Q&A Panel
10:00- 10:20 AM
Break in Exhibit Hall
Session III: Application of Innovative Diagnostic Techniques to the Practice of Clinical Lipidology
10:20- 10:30 AM
ARS Questions
10:30- 11:00 AM
Micro RNA’s as Regulators of Lipid Metabolism: What are the Therapeutic Implications?
Kathryn J. Moore, PhD
11:00- 11:30 AM
What has Intravascular Ultrasound Taught the Clinical Lipidologist?
Steve E. Nissen, MD, FACC
11:30- 12:00 PM
Hypertriglyceridemia: Application of Genetic Insights to Diagnosis and Management
Joseph L. Witztum, MD
12:00- 12:30 PM
ARS Questions and Q&A Panel
12:30- 12:45 PM
NLA News & Notes
12:45- 1:45 PM
Lunch in Exhibit Hall
Session IV: Debates in Lifestyle Therapy
1:45- 1:55 PM
ARS Questions
1:55- 2:05 PM
Saturated Fat and ASCVD Risk: Synthesizing the Evidence for Optimal Patient Care
Penny Kris-Etherton, PhD, RD, FNLA
2:05- 2:15 PM
ASCVD risk Saturated Fat and ASCVD Risk: Examining the Strengths and Limitations of the Evidence
Andrew Mente, PhD
2:15- 2:25 PM
Rebuttal
2:25- 2:35 PM
Saturated Fat is Not a Good Basis for Choosing What to Eat
David R. Jacobs, PhD
2:35- 2:45 PM
All Saturated Fatty Acids Must be Considered in the SFA Recommendations for LDL-C and non-HDL-C lowering
Kevin C. Maki, PhD, FNLA, CLS
2:45- 2:55 PM
Rebuttal
2:55- 3:05 PM
Pro: Aerobic Physical Activity Lowers LDL
Ralph La Forge, MSc, CLS, FNLA
3:05- 3:15 PM
Con: Aerobic Physical Activity Lowers LDL
John M. Jakicic, PhD
3:15- 3:25 PM
Rebuttal
3:25- 3:55 PM
ARS Questions and Q&A Panel
3:55- 4:05 PM
Break
Session V: New Advances in Treatment of Familial Hypercholesterolemia
4:05- 4:15 PM
ARS Questions
4:15- 4:45 PM
FH is More common than Most People Think: Prevalence Data and Practical Aspects of Genetic Testing
Nathan Stitziel, MD, PhD
5:15- 5:45 PM
Familial Hypercholesterolemia from the Patient Perspective
Linda C. Hemphill, MD, FNLA
4:45- 5:15 PM
PCSK9 Inhibitors: Practical Aspects of their use in FH Patients
James A. Underberg, MD, MS, FNLA
5:45- 6:15 PM
ARS Questions and Q&A Panel
7:00- 9:00 PM
Foundation of the NLA Event

Sunday, March 20, 2016

7:00- 7:50 AM
Breakfast
Session VI: Update on Lipid Management in Special Populations
7:50- 8:00 AM
Housekeeping Notes & ARS Questions for Session VI
8:00- 8:30 AM
Management of Dyslipidemia in Women Throughout the Lifespan
Pamela B. Morris, MD, FNLA
8:30- 9:00 AM
Lipid Management to Reduce ASCVD Risk in the Elderly; What is the Evidence?
Joyce L. Ross, MSN, CRNP, CLS, FNLA
9:00- 9:30 AM
Evidence-Based Recommendations for Improving Adherence to Lipid Medication
Lynne T. Braun, PhD, CNP, CLS, FNLA
9:30- 10:00 AM
ARS Questions and Q&A Panel
10:00- AM
Adjourn

The NLA invites speakers and guests to provide scientific medical opinion, which do not necessarily reflect the policy of the NLA. The schedule and faculty are subject to change.

Faculty


Jane F. Barlow, MD, MPH, MBA
Associate Chief Medical Officer CVS Health Scottsdale, AZ

Harold E. Bays, MD, FNLA
President, Southeast Lipid Association Medical Director / President Louisville Metabolic and Atherosclerosis  Research Center Louisville, KY Diplomate, American Board of Clinical Lipidology

Lynne T. Braun, PhD, CNP, CLS, FNLA
Professor of Nursing and Nurse Practitioner Rush University Medical Center Chicago, IL

Anne C. Goldberg, MD, FACP, FNLA
President, Foundation of the NLA Associate Professor of Medicine Washington University School of Medicine St. Louis, MO Diplomate, American Board of Clinical Lipidology

Linda C. Hemphill, MD, FNLA
President, Northeast Lipid Association Instructor in Medicine Harvard Medical School Assistant Physician in Medicine Massachusetts General Hospital Boston, MA Diplomate, American Board of Clinical Lipidology

David R. Jacobs, PhD
Mayo Professor of Public Health Division of Epidemiology and Community Health School of Public Health University of Minnesota Minneapolis, MN

Terry A. Jacobson, MD, FNLA
Immediate- Past President, National Lipid Association Director, Office of Health Promotion and Disease Prevention Professor of Medicine Emory University Atlanta, GA Diplomate, American Board of Clinical Lipidology

John M. Jakicic, PhD
Director, Physical Activity and Weight Management Research Center Department of Health and Physical Activity University of Pittsburgh Pittsburgh, PA

Penny M. Kris-Etherton, PhD, RD, CLS, FNLA
Distinguished Professor of Nutrition College of Health and Human Development Pennsylvania State University University Park, PA

Ralph La Forge, MSc, CLS, FNLA
Clinical Exercise Physiologist Durham, NC

Kevin C. Maki, PhD, CLS, FNLA
Chief Science Officer Provident Clinical Research & Consulting Glen Ellyn, IL

Seth S. Martin, MD, MHS, FACC
Assistant Professor of Medicine Associate Director-  Lipid Clinic  Ciccarone Prevention Center Division of Cardiology Johns Hopkins University School of Medicine Baltimore, MD

Andrew Mente, PhD
Associate Professor Department of Clinical Epidemiology and Biostatistics McMaster University Population Health Research Institute Hamilton Health Sciences Hamilton, Ontario, Canada

Kathryn J. Moore, PhD
Jean and David Blechman Professor of Cardiology Department of Medicine New York University School of Medicine New York, NY

Pamela B. Morris, MD, FNLA
Director, Preventive Cardiology Co-Director, Women’s Heart Care Medical University of South Carolina Charleston, SC Diplomate, American Board of Clinical Lipidology

Steve E. Nissen, MD, MACC
Chairman, Department of Cardiovascular Medicine Cleveland Clinic Foundation Professor of Medicine Cleveland Clinic Lerner School of Medicine Case Western Reserve University Cleveland, OH

Joyce L. Ross, MSN, ANP, CLS, CRNP, FPCNA, FNLA
President-Elect, National Lipid Association Consultative Education Specialist,   Cardiovascular Risk Intervention University of Pennsylvania Health System- Retired Philadelphia, PA

Nathan O. Stitziel, MD, PhD
Assistant Professor of Medicine and Genetics  Director, Center for Cardiovascular Genetics Assistant Director, McDonnell Genome Institute Washington University School of Medicine St. Louis, MO

James A. Underberg, MD, MS, FNLA
Clinical Assistant Professor of Medicine NYU School of Medicine & NYU Center for  Prevention of Cardiovascular Disease Director, Bellevue Hospital Lipid Clinic New York, NY Diplomate, American Board of Clinical Lipidology

Joseph L. Witztum, MD
Distinguished Professor of Medicine University California, San Diego La Jolla, CA

Featured Sessions


PCSK9 Inhibitors: Do the FDA-Approved Indications Mandate Lipid Goals?


Jane BarlowJane F. Barlow, MD, MPH, MBA

Associate Chief Medical Officer

CVS Health

Scottsdale, AZ

 

 

 

Friday, March 18, 2016

4:00–4:30 pm

General Session Room

This presentation will highlight the need to achieve consensus around management strategies for patients with hyperlipidemia. The first two therapies in the new class of drugs – PCSK9 inhibitors – recently received FDA approval. These injectables are highly effective in lowering cholesterol levels. But at a price tag of $14,000 or more per patient each year the costs will add up quickly and further strain limited health care system budgets.

Current guidelines could inadvertently limit the ability to manage utilization of these high-cost agents. The guidelines do not offer sufficient clarity to prescribers to identify appropriate use of PCSK9 inhibitors relative to other treatments, many of which are generic medications available at a much lower cost. This session will explore the role of guidelines in ensuring appropriate access to the drugs, steps taken to manage utilization based on guidelines and the important role of lipid goals in this process.

A thoughtful, disciplined and clinically sound approach to PCSK9 inhibitors and other high-cost medications will help provide patients access to the drugs they need, while lessening the cost burden on the health care system.

Accreditation


Educational Objectives
At the conclusion of this activity, registered nurses and nurse practitioners should be able to provide appropriate counsel for patients and their families.

At the conclusion of this activity, all participants should be able to:

Session I: PCSK9 inhibition: A New Paradigm in LDL-C Reduction

  • Analyze how new therapies may impact current guidelines
  • Describe the role of PCSK9 inhibitors in patients with elevated LDL-C and its impact on apheresis.
  • Assess the data on safety and efficacy of therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9) to provide additional lipid lowering benefits

Session II:  Keeping Up to Date in Clinical Lipidology

  • Discuss the potential role of health information technologies in optimizing lipid management.
  • Review current literature of particular importance to the practice and science of clinical lipidology
  • Describe the efficacy, safety, and mechanisms of action of novel lipid-targeted pharmacotherapies

Session III:  Application of Innovative Diagnostic Techniques to the Practice of Clinical Lipidology

  • Evaluate the role of Micro RNAs in the regulation of lipid metabolism
  • Review the use of newer imaging modalities for screening and preventing coronary artery disease
  • Evaluate the use of genetics to modify lipid therapies in patients with hypertriglyceridemia

Session IV: Debates in Lifestyle Therapy

  • Examine evidence around Current Dietary Recommendations for Heart Health
  • Compare and contrast the impact of saturated fats and diet on their lipid lowering effects
  • Review the role of physical activity on dyslipidemia and cardiovascular risk.

Session V: New Advances in Treatment of Familial Hypercholesterolemia

  • Describe the current and future technologies available for genetic FH screening
  • Identify the potential roles that PCSK9 Inhibitors may play in management of Patients with FH
  • Discuss treatment strategies for familial hypercholesterolemia via case study presentations

Session VI:  Update on Lipid Management in Special Populations

  • Implement appropriate treatment strategies for women with dyslipidemia
  • Assess the evidence evaluating dyslipidemia pharmacology in elderly
  • Review the scientific research relating to adherence to lipid-lowering therapies and the  impact on  treatment decisions

 

CME credit provided by the National Lipid Association

Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Lipid Association designates this live activity for a maximum of 13 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 13 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.

American Academy of Family Physicians
This Live activity, 2016 Spring Clinical Lipid Update- San Diego, CA, with a beginning date of 03/18/2016, has been reviewed and is acceptable for up to 13.00 Elective credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

CE credit provided by Postgraduate Institute for Medicine

Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Session I- Universal Activity Number 0809-9999-16-026-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Session II- Universal Activity Number 0809-9999-16-027-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session III – Universal Activity Number 0809-9999-16-028-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Session IV– Universal Activity Number 0809-9999-16-029-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Session V – Universal Activity Number 0809-9999-16-030-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Session VI – Universal Activity Number 0809-9999-16-031-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Nursing

This educational activity for 12.5 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Session I- 2.1 credits; Session II- 2.0 credits; Session III- 2.1 credits; Session IV- 2.1 credits; Session V- 2.1 credits; Session VI- 2.1 credits.

California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 12.5 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Pre-Conference Courses


The NLA’s Masters in Lipidology Course is an intensive 2-day training course offers an in-depth review of the core curriculum in Clinical Lipidology for health care professionals who desire to practice at an advanced level within the field. Learn from leading experts, assess your knowledge of lipid science and advance your personal standard of practice.
 

The NLA's Lipid Academy provides a comprehensive, in-depth indoctrination to lipid science and is open to all health care professionals interested in developing a core competency in the diagnosis and treatment of dyslipidemia. The interactive Lipid Academy course provides health professionals with the knowledge and tools necessary to work effectively in a lipid practice, and will serve as a preparatory course for the Annual Scientific Forum and other advanced lipid training.
 

 

The NLA coding course Advances in Coding: Exploring ICD-10 Implementations has been designed to assist in assuring accurate coding and reimbursement by offering a variety of educational programs and coding tools.  The course will provide the understanding and skills necessary to ensure the financial health necessary for providing quality care to patients. Attendees will be able to apply the coding and documentation guidelines for problem-oriented and screening services to everyday clinical practice. Understanding how to properly select evaluation and management codes, as well as preventive codes will improve reimbursement and ensure compliance with applicable guidelines and regulations.

Abstracts


Abstracts Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Foundation Event


 

 

Support the Foundation of the NLA by attending the exciting event below that will take place in conjunction with the 2016 Spring Clinical Lipid Update.

 

dinner detectiveThe Dinner Detective
Saturday, March 19, 2016
6:30-9:15 PM
$85 per person

 

Join us on the evening of March 19th for a murder mystery comedy dinner show, designed just for our group. Laugh, interact and attempt to solve the mystery with colleagues during the show. Hor d’Oeuvres, dinner and dessert to accompany the fun filled evening.

dinner detective

Cash bar will be available.

The event is walking distance from the Omni Hotel.

CME Symposia


Saturday, March 19, 2016
6:00am Breakfast and Registration
6:15am-7:45am Educational Activity

Omni San Diego Hotel
Ground Floor, Gallery 1 and 2
San Diego, California

Overview
Several controversies and questions related to the management of dyslipidemia currently exist. Accordingly, this activity will consist of point-counterpoint discussions of several critical questions, including the role of guidelines and recommendations in the treatment of individual patients with dyslipidemia and the utility of lipid goals and threshold treatment values. The impact of statin trial study designs, as it relates to atherosclerotic cardiovascular disease (ASCVD) outcomes and lipid goals, will also be explored. The role of HDL-C in ASCVD risk and whether it is a viable lipid treatment target will be discussed, and the definition of residual risk will be presented with discussion of how residual risk is best understood and treated. These contemplations will be delivered by experts in lipid management and will provide healthcare providers an opportunity to stay up-to-date with the best available evidence so that they may safely and effectively incorporate new information and medications into their clinical decision making for patients with dyslipidemia and risk for ASCVD.

Faculty

James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
Activity Moderator/Chairperson
Clinical Assistant Professor of Medicine,
Division of General Internal Medicine
NYU School of Medicine
Center for the Prevention of Cardiovascular Disease
NYU Langone Medical Center
Director,
Bellevue Hospital Primary Care Lipid Management Clinic
New York, New York

Harold Bays, MD, FTOS, FACC, FACE, FNLA
Medical Director and President,
Louisville Metabolic and Atherosclerosis Research Center
Louisville, Kentucky

Peter Howard Jones, MD, FACP, FNLA
Medical Director, Weight Management Center
Houston Methodist Diabetes & Metabolism Institute
Associate Professor of Medicine,
Co-Director, Lipid Metabolism and Atherosclerosis Clinic
Center for Cardiovascular Disease Prevention
Houston Methodist DeBakey Heart & Vascular Center
Baylor College of Medicine
Houston, Texas

Agenda

6:00 AM Breakfast and Registration
6:15 AM

Program Overview
James A. Underberg, MD, MS, FNLA

6:25 AM Principles of Lipid Guidelines and Goals
Harold E. Bays, MD, FNLA
Peter H. Jones, MD, FNLA
6:55 AM Role of HDL, HDL-C, and Residual ASCVD Risk in Managing Patients With Dyslipidemia
Harold E. Bays, MD, FNLA
Peter H. Jones, MD, FNLA
7:25 AM Question & Answer Session
7:45 AM Adjournment

 

Target Audience
This activity is designed for clinical cardiologists, primary care clinicians, physician assistants, pharmacists, advance practice registered nurses, registered nurses, and registered dietitians who are interested in the current controversies in dyslipidemia management.

Learning Objectives
Upon completion of the activity, participants should be able to:

  1. Develop an individualized management approach for patients with dyslipidemia and residual cardiovascular risk considering the similarities and differences among the various clinical practice guidelines related to LDL-C, HDL-C, and nonstatin therapy.
  2. Evaluate the evidence on the role of HDL-C in dyslipidemia management to determine where patients may benefit from therapeutically targeting HDL-C.
  3. Review the data regarding the safety and efficacy of more recent and investigational treatments for LDL-C and other lipid parameters, such as PCSK9 and CETP inhibitors, for patients with dyslipidemia.

At the conclusion of this activity, registered nurses and nurse practitioners should be able to provide appropriate care and counsel for patients and their families.

CREDIT DESIGNATION

CME credit provided by the National Lipid Association

Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Lipid Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1 Continuing Professional Education Units (CPEUs) for completion of this activity. CDR Accredited Provider #NL0002.

CE Credit provided by Postgraduate Institute for Medicine

Pharmacists

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Universal Activity Number 0809-9999-16-086-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (.15 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
This educational activity for 1.5 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

California Board of Registered Nursing: Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.5 contact hours.

Disclosure Statement
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

Criteria for Success
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme.
For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

This activity is jointly provided by The National Lipid Association.

This activity is jointly provided by Postgraduate Institute for Medicine.

This activity is facilitated by Forefront Collaborative.

 

Acknowledgement Statement
Supported by an educational grant from Lilly and Sanofi US and Regeneron Pharmaceuticals. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Expert Theatre


Interested in hosting an Expert Theatre in conjunction with the NLA’ Spring Clinical Lipid Update in San Diego? Please contact Leia Hutfles lhutfles@lipid.org for more information. Availability is limited. 

Honors and Awards Ceremony


Honors and Awards Ceremony Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Mentor and Mentee Reception


Mentors and Mentees Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Mobile App


New in 2016! The National Lipid Association will be providing an app with onsite updates and educational content for attendees. More information coming soon about how to download the app in preparation for the meeting.

Support Recognition

Accreditation Council for Clinical Lipidology (ACCL)
The ACCL establishes, certifies, and maintains the clinical competencies of qualified and experienced healthcare professionals specializing in Clinical Lipidology (non-physician and physician). Two levels of certification offered: Clinical Lipid Specialist (CLS) and Lipid Competency Certificate (LCC).
www.lipidspecialist.org

Akcea Therapeutics
Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc., is focused on the development and commercialization of new treatments for patients with serious cardiometabolic lipid disorders.
www.akceatx.com

American Board of Clinical Lipidology (ABCL)
The ABCL assesses and validates the specialized knowledge and advanced training required to practice in the dynamic and complex field of Lipidology.  The only certification program of its kind available to licensed physicians in the United States or Canada.     
www.lipidboard.org

Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
www.amgen.com

Blueprint Genetics
Blueprint Genetics is a genetics company in Helsinki and San Francisco. We are a team of cardiologists, geneticists, bioinformaticians and DNA biologists providing comprehensive and high quality genetic diagnostics with Next-Generation Sequencing.
www.blueprintgenetics.com

Boston Heart Diagnostics
Boston Heart is transforming the treatment of cardiovascular disease by providing healthcare providers and their patients with novel, personalized diagnostics and reports with integrated, customized lifestyle programs.
www.bostonheartdiagnostics.com

Carlson Labs
Since 1965, Carlson Laboratories has produced the freshest, purest, award-winning vitamins, minerals, fish oils, and other nutritional supplements.  We continue to remain on the forefront of innovation and are proud to offer an advanced product line with over 250 innovative formulas designed with all of your nutritional needs in mind.”
www.carlsonlabs.com

Kaneka Pharma America
Kaneka’s Liposorber Apheresis System is FDA approved for the acute reduction of LDL cholesterol (70-80%) in patients with Familial Hypercholesterolemia and patients who cannot meet their LDL-C goals despite maximum drug therapy. The Liposorber treatment is reimbursed by government and private insurance, and is used in hospitals, clinics, and physician offices across the country.
www.liposorber.com

Kowa Pharmaceuticals America, Inc.
Kowa Pharmaceuticals America, Inc. delivers value-based solutions to patients by investing in the advancement of cardiometabolic therapeutics. The company's flagship product is LIVALO® (pitavastatin) tablets 1mg, 2mg, 4mg.
www.livalohcp.com

Quantimetrix Corporation
Description Coming Soon
www.quantimetrix.com

Quest Diagnostics
Quest Diagnostics, the world’s leading provider of diagnostic testing, information and services, offers the Cardio IQ Solution—a comprehensive approach to heart health.  Visit 4myheart.com and QuestDiagnostics.com.
www.QuestDiagnostics.com
 

ReachMD
ReachMD is an award-winning medical broadcasting company delivering education and information to healthcare professionals nationwide through an on air, online, and mobile distribution network.
www.reachmd.com

Sanofi-Regeneron
Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.
www.regeneron.com

Interested in supporting the NLA’s 2016 programs, please contact Leia Hutfles, Meeting Coordinator (p) 904-309-6207 (e) lhutfles@lipid.org.

Virtual Exhibit Hall


Virtual Exhibit Hall Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Industry Council


Industry Council coming soon...

Media Partners


Cardiology Today

   

 

 

 

 

 

 

 

Omni San Diego Hotel

 

omni hotelOmni San Diego Hotel
675 L Street
San Diego, CA 92101

 

Meeting Room Rate: $229/night ++
Room Reservation Cut-Off Date: February 18, 2016

For reservations call 1-800-THE-OMNI and ask for the National Lipid Association room rate.

 

 

 

The newly renovated four-star Omni San Diego Hotel is located in the heart of the historic Gaslamp Quarter. Omni San Diego Hotel puts you close to the city's top sites and attractions. Omni Hotels & Resorts makes every stay memorable, unique and authentic to the local culture by taking personal service to heart. Each Omni property blends seamlessly into the local culture while featuring four-diamond services, signature restaurants, WiFi connectivity and unique wellness options.

terraceTower Harbor

 

Local Attractions

San Diego ZooSan Diego Zoo
The San Diego Zoo has been voted the number one zoo in the world. The 100-acre Zoo is home to over 3,700 rare and endangered animals representing more than 650 species and subspecies, and a prominent botanical collection with more than 700,000 exotic plants. It is located just north of downtown San Diego in Balboa Park.

 

 

USS Midway MuseumUSS Midway Museum
Imagine experiencing life at sea aboard one of America’s longest-serving aircraft carriers. Visitors to the USS Midway Museum enter a floating city at sea and walk in the footsteps of 225,000 Midway sailors who served our country and upheld the American ideals of strength, freedom and peace.

 

 

 

maritime museumMaritime Museum of San Diego
The Maritime Museum of San Diego enjoys a worldwide reputation for excellence in restoring, maintaining and operating historic vessels. The museum has one of the world’s finest collections of historic ships, including the world’s oldest active ship Star of India. The collection of ships and exhibits are available for daily public tours.

 

 

 

Cabrillo national MonumentCabrillo National Monument
Climbing out of his boat and onto shore in 1542, Juan Rodriguez Cabrillo stepped into history as the first European to set foot on what is now the West Coast of the United States. In addition to telling the story of 16th century exploration, the park is home to a wealth of cultural and natural resources.

 

 

 

 

Gaslamp QuarterGaslamp Quarter
Though the Gaslamp Quarter Association was officially chartered in 1982 by the City of San Diego under State Law, the Gaslamp Quarter’s Merchant Association goes back several decades and the historic commercial district that would become the Gaslamp Quarter began as William Heath Davis’ New Town in 1850. The Gaslamp Quarter’s colorful history, combined with its modern-day, world-class boutiques, galleries, and restaurants, is what makes this urban district unlike any other.

Exhibit in San Diego



Several hundred health professionals will gather at the 2016 NLA Spring Clinical Lipid Update to benefit from comprehensive education sessions, to interact with their colleagues and to explore the exhibit hall.  Sponsorships and exhibits are designed to provide a solid platform to help you stand out and make an impact.  As an exhibitor, increase your presence at this meeting by taking advantage of exhibitor-only sponsorship opportunities and showcase what your company has to offer.

We look forward to you having you join us in San Diego.

Exhibitors Move In

FRIDAY, MARCH 18TH

10:00 AM-4:00 PM

EXHIBIT Hall aisles must be cleared of boxes and crates and booth construction completed by Friday, March 18, 2016 at 4:00 PM.

 

Exhibit Hall Hours

FRIDAY, MARCH 18TH

6:00 PM - 7:00 PM

Welcome Reception in Exhibit Hall

SATURDAY, MARCH 19TH

7:00 - 7:50 AM

Breakfast in Exhibit Hall

10:00 - 10:20 AM

Break in Exhibit Hall

12:45 - 1:45 PM

Lunch in Exhibit Hall

2:00 PM

Exhibitors Move Out

 

Exhibit and sponsorship packages available. For more information or questions, please contact:
Leia Hutfles, Meeting Coordinator
(p) 904-309-6207 (e) lhutfles@lipid.org

Register for 2016 Spring Clinical Lipid Update

Personal Information

Contact Information

Which meetings or courses would you like to attend?

Must be logged in to click NLA member price
NLA Member
Early Bird Rate

Before 2/6/16
NLA Member
Discounted Rate

After 2/6/16
Non-Member
Rate
Trainee
Rate*
Spring Clinical Lipid Update**
March 18-20, 2016
$495.00
$545.00
$895.00
$75.00
Professional Development
Masters in Lipidology Course
March 17-18, 2016
$750.00
$750.00
$1250.00
$395.00
Lipid Academy
March 17-18, 2016
$550.00
$550.00
$950.00
$0.00
NLA Coding Course
March 18, 2016
$200.00
$200.00
$200.00
$200.00
Special Events and Guest Fees
Foundation Event- The Dinner Detective
$85 x
Guest Pass- Exhibit Hall
$150 x

*Non-Member Trainees must register with .PDF form.
**Includes one admission badge to Exhibit Hall for all food functions.

Total

$0.00

Payment Information

Registration: Registration and payment must be received no later than February 26, 2016. After this, date meeting materials and name badge cannot be guaranteed.

Cancellation: Telephone cancellations will not be accepted. A written notice of cancellation must be received no later than February 26, 2016. This includes social events and guest fees. There will be a $100 fee for all cancellations.

ADA Compliance: Attendees who need additional reasonable accommodations or who have special needs should contact the NLA at 904.998.0854.

Trainee Rate: Available for those individuals actively enrolled in a graduate or postgraduate training program for the treatment or investigation of lipid disorders and in pursuit of full credentialing in their specialized area of medical study. A letter from the program director or the school registrar must accompany the application.

by Dr. Radut.